Abstract Details

Title A case series of metastatic glioblastoma at Memorial Sloan Kettering Cancer Center

Topic Neuro-oncology

Presentation(s) P1 - Poster Session 1 (5:30 PM-6:30 PM)

Poster/Presentation
Number 7-008

Objective To describe the experience of patients with metastatic glioblastoma at Memorial Sloan Kettering Cancer Center.

Background Extracranial metastasis of glioma is a rare event during the progression of this type of brain tumor, often occurring in patients with advanced disease. Though intracranial glioblastoma continues to carry a poor prognosis, extracranial metastasis is a particularly unfavorable factor in survival.

Design/Methods We conducted a retrospective case series of patients with metastatic glioblastoma diagnosed at Memorial Sloan Kettering Cancer Center between 2003 and 2018, including only patients with biopsy-confirmed sites of metastatic disease.

Results We present 11 patients with metastatic extracranial glioblastoma or gliosarcoma. 7 patients had glioblastoma, 3 patients had gliosarcoma, and 1 patient had ganglioglioma that progressed to gliosarcoma. The age at diagnosis ranged from 14 to 73, with 7 men and 4 woman. The median overall survival from initial diagnosis and from diagnosis of extracranial metastasis was 13.2 (range 9.2-57.2) and 5 (range 1-16.1) months, respectively. The most common site of extracranial metastatic disease was bone, with other sites being cervical and thoracic lymph nodes, liver, lung, and soft tissues. 8 patients had symptoms referable to their site of extracranial metastasis, with the most common symptoms being pain and shortness of breath. All patients received initial surgical resection, followed by radiation and temozolomide, with subsequent chemotherapeutic regimens administered that were most appropriate for their individual cases.

Conclusions These cases demonstrate several risk factors for extracranial metastasis of glioblastoma and gliosarcoma, namely disruption of normal anatomic barriers during surgical resection and sarcomatous dedifferentiation. Next steps with this work include further analysis of the molecular features of extracranial glioblastoma metastases with respect to the site of primary disease, which we anticipate will lead to a better understanding of the molecular mechanisms of metastasis and may improve treatments for these patients.

Authors/Disclosures
Evan Noch, MD (New York Presbyterian Hospital, Weill Cornell Medical Center) PRESENTER	Dr. Noch has received personal compensation for serving as an employee of Destroke, Inc.. Dr. Noch has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lexeo Therapeutics. Dr. Noch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Advarra, Inc.. Dr. Noch has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Imedview, Inc.. Dr. Noch has stock in Destroke, Inc..
	No disclosure on file
Alexandra M. Miller, MD (NYU Langone Department of Neurology)	Dr. Miller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Miller has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Modifi Biosciences.

��ɫ��

��ɫ��